Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Golubnitschaja, Olga ^a   Yeghiazaryan, Kristina ^a   Stricker, Helena ^a   Trog, Daniela ^b   Schild, Hans H ^a   Berliner, Leonard ^c  

^a UNIVERSITY OF BONN   (Germany)

^b Radiox Strahlentherapie Hamm   (Germany)

^c NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

Biobanking; Blood test; Breast cancer; Hepatic carcinoma; Matrix metalloproteinase patterns; Metastasis; Patient stratification; Predictive preventive personalised medicine; Prognosis; SIRT

Indexed keywords

GELATINASE A; GELATINASE B; YTTRIUM 90; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; YTTRIUM;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; BREAST METASTASIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIXED ADENONEUROENDOCRINE CARCINOMA; MORTALITY RATE; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS CANCER; SELECTIVE INTERNAL RADIATION THERAPY; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER; UVEA MELANOMA; BLOOD; BRACHYTHERAPY; BREAST NEOPLASMS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES; RADIATION RESPONSE; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; BRACHYTHERAPY; BREAST NEOPLASMS; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84975763955     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2382-2     Document Type: Article

References (25)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 1990. 2013;49(6):1374-403.
2. Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Interv Radiol. 2006;23(1):47-63.
3. Kümler I, Parner VK, Tuxen MK, Skjoldbye B, Bergenfeldt M, Nelausen KM, et al. Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer. Radiol Med. 2015;120(6):536-41.
4. Ihnenfeld Arciénega I, Imesch P, Fink D, Dedes KJ. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. Target Oncol. 2015;10(2):297-301.
5. Catteau X, Simon P, Noël J-C. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol. 2014;9:196.
6. Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, et al. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy. PLoS One. 2014;9(10):e109611.
7. Turhan N, Esendagli G, Ozkayar O, Tunali G, Sokmensuer C, Abbasoglu O. Co-existence of Echinococcus granulosus infection and cancer metastasis in the liver correlates with reduced Th1 immune responses. Parasite Immunol. 2015;37(1):16-22.
8. Makita M, Sakai T, Ogiya A, Kitagawa D, Morizono H, Miyagi Y, et al. Optimal surveillance for postoperative metastasis in breast cancer patients. Breast Cancer. 2016;23(2):286-94. doi: 10.1007/s12282-014-0571-x.
9. Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, Stolz DB, et al. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer. 2014;111(12):2342-50.
10. Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125-33.
11. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One. 2011;6(7):e21816. doi: 10.1371/journal.pone.0021816.
12. Lu Y, Zhu M, Li W, Lin B, Dong X, Chen Y, et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J Cell Mol Med. 2016;20(3):549-58. doi: 10.1111/jcmm.12745.
13. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014;5(9):2736-49.
14. Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, et al. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 2015;17:45. doi: 10.1186/s13058-015-0558-3.
15. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000;21(5):867-76.
16. Berliner L, Lemke HU, vanSonnenberg E, Ashamalla H, Mattes MD, Dosik D, et al. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J. 2014;5(1):16.
17. Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Springer; 2015. Available from: http://www.springer.com/de/book/9783319121659. Accessed 20 Oct 2015.
18. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):800-4.
19. Jakobs TF, Hoffmann R-T, Fischer T, Stemmler H-J, Tatsch K, La Fougere C, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19(5):683-90.
20. Cianni R, Pelle G, Urigo C, Saltarelli A, Notarianni E, Pasqualini V, et al. Radioembolization of breast hepatic metastasis with SIR spheres loaded with yttrium-90 (Y-90). J Clin Oncol. 2011;29(Suppl):e11577. 29.
21. Korse CM, Bonfrer JMG, Prevoo W, Baas P, Taal BG. Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumour Biol. 2011;32(4):647-52.
22. Daniele A, Divella R, Quaranta M, Mattioli V, Casamassima P, Paradiso A, et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization. Clin Biochem. 2014;47(3):184-90.
23. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409-25.
24. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res. 2012;10(11):1403-18.
25. Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O. Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows. Pers Med. 2011;8(3):321-30.